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Abstract. One of the mutations in the microtubule-associated protein tau, P301S, is causative for dominantly inher-
ited frontotemporal dementia characterized by extensive tau pathology for which no licensed treatment is available.
Hydromethylthionine is a potent tau aggregation inhibitor. We report treatment of an asymptomatic carrier of the P301S
mutation using hydromethylthionine over a 5-year period beginning at the mean age of onset of clinical decline in the family.
During the period of treatment, the rates of progression of cerebral atrophy were reduced by 61%–66% in frontal and temporal
lobes, and the patient remained clinically asymptomatic.
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INTRODUCTION
One of the mutations in the microtubule-associated
protein tau (MAPT) gene in frontotemporal dementia
(FTD) occurs in exon 10 (g123789 C > T) which leads
to a substitution of proline at position 301 by serine
∗Correspondence to: Claude Wischik, TauRx Therapeutics
Ltd., 395 King Street, Aberdeen AB24 5RP, United Kingdom.
E-mail: cmw@taurx.com.
(P301S) [1]. A worldwide cohort study of age at
symptom onset, disease duration, and death in genetic
FTD identified 20 P301S cases from 5 families [2].
The mean ages of clinical onset and death were 34.3
(N = 15) and 40.8 (N = 10) years, respectively. At
clinical presentation, structural imaging shows vari-
ous combinations of frontotemporal and parietal lobe
atrophy with ventricular enlargement [1, 3–6]. Per-
fusion and metabolic deficits are reported in similar
areas and also in the thalamus. For cases with MAPT
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mutations, structural imaging changes can be iden-
tified 5–10 years before expected symptom onset,
occurring first in the temporal and medial tempo-
ral lobes (hippocampus and amygdala) [7]. The rate
of temporal atrophy increases as symptoms develop,
followed by atrophy of the frontal and parietal lobes
[8], and progresses more rapidly than in Alzheimer’s
disease (AD) [9, 10].
There are currently no licensed treatments for any
form of FTD. Hydromethylthionine mesylate (also
known as leuco-methylthionine bis(hydromesylate);
LMTM) is being developed by TauRx Therapeu-
tics for treatment of AD [11, 12] and behavioral
variant FTD (bvFTD) [13]. The reduced LMT form
of methylthionine has been shown to be the active
species blocking tau aggregation in vitro [14], with
a site of action within the proteolytically stable core
tau unit of the tau aggregates found in both AD and
FTD [15–17]. The oxidized MT+ species present in
methylthioninium chloride (MTC) requires conver-
sion to the leucomethylthioninium (LMT) form to
permit cell uptake [18]. LMTM was tested in a Phase
III clinical trial in 220 patients with behavioral vari-
ant FTD in which 200 mg/day was compared with
8 mg/day intended as an inactive control for urinary
discoloration. A post-hoc population pharmacoki-
netic (PK) analysis in 171 of the 220 subjects revealed
a steep exposure-response relationship in the group
receiving the 8 mg/day dose and no additional benefit
at 200 mg/day [13]. The majority (65%) of patients
receiving 8 mg/day had steady-state plasma levels
above a threshold of 0.346 ng/ml, defined on the basis
of the lower calibration limit of the assay. These had
significantly less cognitive and functional decline and
reduced brain atrophy over 12 months when com-
pared to the 35% of patients with low plasma levels at
the same dose [13]. Essentially identical results were
found in two similarly designed trials in AD [19].
Therefore, 8 mg/day is the minimum effective dose
of LMTM in both AD and bvFTD [12, 20], although
the predicted optimum doses differ: 16 mg/day in AD
and 20–60 mg/day in bvFTD. By contrast, the min-
imum effective dose using MTC was found to be
138 mg/day in a Phase II trial in AD [21]. This dose
of MTC was used to treat a 46-year-old patient with
sporadic bvFTD [22]. The authors reported clinically
relevant, sustained improvements in behavior, motor
abilities, and function over a 6-month period. The
present study reports the successful treatment of an
asymptomatic carrier of the P301S mutation using
LMTM over a period of 5 years beginning at the mean
age of onset of clinical decline in the family.
CLINICAL AND LMTM TREATMENT
DATA
A 32-year-old male was assessed in a UK teaching
hospital having tested positive for the MAPT muta-
tion c.901C > T (g123789 C > T) in exon 10 (CCG
to TCG) (Pro301Ser) (Medical Genetics Service
Molecular Genetics Laboratory, Addenbrooke’s Hos-
pital Cambridge). The known family history spans
four generations and includes 10 cases. The mean
age of clinical onset for this family is 38.4 years
(N = 5) and the mean age of death is 40.4 years
(N = 8). At initial assessment, he had no cognitive
complaints but was depressed about the positive test
result and was treated with fluoxetine. The informant
history described irritability but no other symptoms
suggestive of bvFTD. There were no neurologi-
cal abnormalities. On the Addenbrooke’s Cognitive
Examination-Revised (ACE-R) he scored 89 with
poor phonemic fluency. On psychometric assessment
WTAR estimated IQ was 76, consistent with his long-
standing difficulties with reading ability. The WASI
FSIQ was average (107). WMS-III index scores
ranged from 89 (immediate memory) to 99 (work-
ing memory). On tests more specific for frontal lobe
function, performance was either average or above
average (Hayling verbal suppression 7; Brixton spa-
tial anticipation 6, FAS 34). His MRI scan at that time
showed no significant brain abnormality.
Within 12-months the depressive symptoms re-
solved, and the subject returned to work as an
electrician. Subsequent annual reviews revealed no
significant symptoms. Six years later, approaching
the age of 38, the subject expressed concern because
another family member had developed symptoms at
a similar age and declined rapidly. A repeat MRI
scan showed no significant abnormality or inter-
val change, whereas the HMPAO-SPECT scan
showed significant bilateral fronto-temporal perfu-
sion deficits which were worse on the left.
The subject was asymptomatic with no evidence
of frontal or temporal atrophy and was therefore
ineligible for the ongoing TauRx clinical trial in
bvFTD (TRx-237-007; NCT01626378). However, as
he had a strong family history, was close to the
age of expected symptom onset and had an abnor-
mal HMPAO-SPECT scan, compassionate treatment
with LMTM was requested and commenced in Jan-
uary 2016. The subject provided written informed
consent for treatment and verbal witnessed consent
for anonymized publication of results. Cognition was
monitored annually using the ACE-3 [23] and clinical
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Fig. 1. Dosing of LMTM administered to subject and progression
of ACE-3 score.
disease severity was assessed using the Frontotem-
poral Dementia Rating Scale (FRS) [24]. Full blood
count including reticulocytes, biochemistry, and vita-
mins B12 and folate were monitored 3-monthly. The
doses of LMTM used and the corresponding ACE-3
scores are summarized in Fig. 1. LMTM was well
tolerated at all the doses given. Dosing decisions
were based on the results emerging from the pop-
ulation PK analyses of data from the bvFTD trial
summarized above. Despite commencing treatment
at the expected age of clinical onset, there was no
decline in the ACE-3 score over the subsequent 61
months of treatment. At month 58, two FRS items
were rated as ‘sometimes’ (restlessness and change
in food preference), but no behavioral change was evi-
dent at interview. At month 61, the informant reported
complete resolution. The safety findings were in line
with those previously reported in AD and bvFTD
studies [11–13], with urinary frequency noted at the
300 mg/day dose, and bilirubin and reticulocyte ele-
vation at both high and low doses.
NEUROIMAGING DATA
The patient had two MRI scans prior to initiation
of LMTM treatment (May 2010 and June 2015) and
two further scans in May 2019 and August 2020 while
on treatment. HMPAO-SPECT scans were performed
in October 2015 and again in July 2019. We used
the 2010, 2015, and 2019 MRI images for further
analysis because they were of comparable quality
and because HMPAO-SPECT scans were also avail-
able in 2015 and 2019. There was no change evident
between the 2019 and 2020 MRI scans. The three
sagittal MRI images are shown in Fig. 2A. These were
acquired with three different machines: a Siemens
Sonata (2010), a Signa Excite (2015), and a Signa
Explorer (2019) all at 1.5 Tesla, using a T1-weighted
2D spin echo sequence with in plane pixel sizes of
0.69, 0.71, and 0.72 mm and slice thicknesses of 6.5,
6.0, and 6.0 mm, and the TR/ET were 449/14, 460/13,
and 517/13, respectively. These images were of suffi-
cient quality to permit analysis of atrophy rates in
frontal and temporal lobes using an in-house ver-
sion of the brain boundary shift integral (BBSI) [25]
and the ICBM (International Consortium for Brain
Mapping) template.
Table 1
Rates of progression of brain atrophy in frontal and temporal lobes before (2010–2015) and while receiving treatment with LMTM
(2015–2019) compared with rates of atrophy calculated from data reported by Chen et al. data [8]
Subjects Frontal Temporal
Case Lobe (cm3/y, Change in Lobe (cm3/year, Change in
[rate %/y]) rate (%) [rate %/y]) rate (%)
2010–2015 –1.54 [–0.88%] –0.72 [–0.73%]
2015–2019 –0.52 [–0.30%] –66.3 –0.28 [–0.28%] –61.0
Case Cortex GM (cm3/y, Change in Cortex GM (cm3/y, Change in
[rate %/y]) rate (%) [rate %/y]) rate (%)
2010–2015 –0.85 [–0.86%] –0.54 [–0.91%]
2015–2019 –0.29 [–0.29%] –65.9 –0.21 [–0.35%] –61.1
Chen et al. Cortex GM (cm3/y, Change in Cortex GM (cm3/year, Change in
[rate %/y]) rate (%) [rate %/y]) rate (%)
Asymptomatic –0.81 [–0.57%] –0.94 [–0.74%]
Converter –1.44 [–0.84%] +77.8 –1.62 [–1.42%] +72.3
Non-Carrier –0.55 [–0.40%] –0.41 [–0.35%]
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Fig. 2. A) Sagittal MRI images acquired in 2010, 2015 and 2019. B) HMPAO-SPECT scan images acquired in 2015 and 2019. C) Rendered
images using NeuroGamTM (http://www.segamicorp.com) outputs showing Z scores from the normal range of a control group aged 16 to
45 years with data normalized to cerebellum. Green represents >2 standard deviations below the mean, light blue > 3, dark blue > 4, black
> 5. Red represents greater than 2 standard deviations above the mean.
The calculated rates of progression of atrophy
per annum are summarized in Table 1 for the 5-
year period (2010–2015) when the subject was an
asymptomatic carrier and the 4-year period of treat-
ment with LMTM (2015–2019) when he would have
been expected to convert to the symptomatic phase
of the condition. Compared with the pre-treatment
period, treatment with LMTM was associated with a
66% reduction in the frontal lobe atrophy rate (from
0.88%/year to 0.30%/year) and a 61% reduction in
the temporal lobe atrophy rate (from –0.73%/year
to –0.28%/year). These were compared with atrophy
rates expected from non-carriers, and asymptomatic
and symptomatic carriers of MAPT mutations calcu-
lated from the data reported by Chen et al. [8] for
subjects of comparable mean age at first scan (36
for non-carriers, 31 for asymptomatic carriers, and
39 for the symptomatic group). The presymptomatic
rates are comparable to those reported by Chen et
al. Conversion to the symptomatic phase is associ-
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ated with an increase of +78% (from –0.57%/year
to –0.84%/year) in frontal cortex atrophy rate and
+72% (from –0.74%/year to –1.42%/year) in tem-
poral cortex atrophy rate (Table 1). By contrast, the
rates following treatment with LMTM were similar
to those calculated for non-carriers (–0.40%/year in
frontal cortex and –0.35%/year in temporal cortex).
Figure 2B also shows the HMPAO-SPECT images
from 2015 and 2019. Areas of abnormal perfusion
can be seen in frontal and temporal lobes in the 2015
images, particularly on the left. The rendered images
(Fig. 2C) show comparisons with the Z scores from
the range of a control group aged 16 to 45 years nor-
malized to cerebellum. Both sets of images show that
the areas of impaired perfusion seen in 2015 were
reduced following treatment with LMTM.
COMMENTARY
In the context of what is known about this rare form
of FTD, it is unexpected that the subject remained
in employment, asymptomatic, functionally inde-
pendent, and cognitively stable into his 44th year.
The mean age of symptom onset among carriers in
the same family is constant and this association is
strongest for MAPT mutations [2, 7]. The mean age
of symptom onset for the subject’s family is 38.4
years (SD 2.1) and the latest known age of onset with
the P301S mutation is 42 years. LMTM treatment
was commenced at the age of 38 when conversion
to the symptomatic phase would have been expected
and when the HMPAO-SPECT scan showed fronto-
temporal perfusion deficits.
During the 5-year treatment period with LMTM,
cognition measured on the ACE-3 did not decline
below the baseline value of 90. Naming, which is
known to be affected early in genetic FTD due to
MAPT mutations [7, 26], remained unimpaired. The
FRS items, restlessness & change in food preference,
were rated as being sometimes present at one assess-
ment but were not present 3 months later and no
behavioral change was evident at the last assessment
reported in March 2021.
The rates of atrophy prior to LMTM treatment
were similar to those expected from the Chen et
al. [8] data for asymptomatic carriers and approx-
imately double the rates observed in non-carriers.
Following treatment with LMTM, these were reduced
by 61%–66% to rates similar to those seen in non-
carriers of comparable age. This contrasts with the
increase of 72%–78% that would have been expected
after the age of 38 when conversion to the symp-
tomatic phase typically occurs in this family. The
reduction in brain atrophy rate was also associated
with a reduction in the perfusion deficits that had
supported initiation of treatment.
The efficacy of LMTM in this case is supported by
reductions in atrophy rates and perfusion deficits and
indirect clinical comparisons with this and similar
kindreds. Normalization of brain atrophy rates and
reduction in progression of functional scan deficits
following treatment with LMTM have been reported
previously in mild AD [12], and the results are also
consistent with those reported recently in a trial
in patients with sporadic bvFTD [13]. The present
results are obviously limited by the fact that they
come from a single case, albeit with consistent clin-
ical and imaging observations over a 10-year period.
The findings need to be confirmed in a randomized
placebo-controlled trial in larger case series to pro-
vide a reliable clinical trial basis for the preventative
use of LMTM for carriers of MAPT mutations for
whom no treatment is currently available.
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